Efficacy of novel kinase inhibitors further validates Creabilis’ low systemic exposure (LSE) technology
Canterbury, UK – 9th December 2015 – Creabilis, the dermatology company with an advanced targeted topical treatment in development for chronic pruritus (itch), today announces that two novel kinase inhibitor drugs for the treatment of atopic dermatitis and psoriasis, investigated with support from a European Union Seventh Framework Programme for Research (FP7) grant, have been selected for further development.
Creabilis and its consortium partners, which included the University of Dundee (UK), Serichim (Italy) and KWS Biotest (UK), received a EUR 1.5 million grant to work together with the aim of identifying novel compounds to treat topical inflammatory-related diseases with low systemic effects by exploiting a systems biology approach.
Two innovative selective kinase inhibitors, CT101 and CT103, targeting atopic dermatitis and psoriasis respectively, showed promising results. Both molecules demonstrated high local efficacy and a favourable safety profile in pre-clinical in vivo testing that strongly recommend further development. CT101 and CT103 exploit innovative modes of action against new kinase targets and were synthesised using Creabilis’ LSE technology, a proprietary platform technology geared for the creation of topical therapies with high local concentration, minimising systemic side effects.
Silvio Traversa, Chief Scientific Officer, commented: “These two molecules demonstrated very promising results in pre-clinical in vivo testing and show potential for the treatment of atopic dermatitis and psoriasis with low systemic effects, key strengths of Creabilis’ proprietary LSE technology. We believe they offer promise of a real improvement in the quality of life of patients with atopic dermatitis and psoriasis, two areas of high unmet medical need.”
Alex Leech, Chief Executive Officer of Creabilis, commented: “The success of this research project gives us even greater confidence in the potential of our unique platform to generate novel treatments for dermatological conditions and adds two highly exciting drug candidates to our already strong dermatology focused pipeline.”
-Ends-
Notes to Editors:
About FP7
FP7, the 7th Framework Programme for Research and Technological Development, is a European Union funding programme for research and innovation, lasting from 2007 to 2013, which had a total budget of EUR 50 billion. Its goal was to strengthen the scientific and technological base of European industry and to encourage international competitiveness while promoting research that supports EU policies.
About Creabilis
Creabilis is a specialty pharmaceutical company focusing on the development of novel topical treatments in the field of dermatology, including its lead product CT327, an advanced targeted topical treatment in development for chronic pruritus (itch). Creabilis has delivered positive Phase 2b results for CT327 in the treatment of pruritus in psoriasis patients. CT327 was developed using Creabilis’ proprietary Low Systemic Exposure (LSE) ‘topical-by-design’ technology that creates molecules optimized for topical applications. Planning for Phase 3 trials with CT327 are underway, with a clear route to the pruritus market via the initial indication of pruritus due to psoriasis. Creabilis’ pipeline also includes CT340, an IND-ready and potent narrow spectrum kinase inhibitor in development for the topical treatment of pruritus due to atopic dermatitis.
Creabilis is backed by highly respected life science investors Sofinnova Partners, Neomed and AbbVie Biotech Ventures Inc., and is led by an experienced management team. Creabilis’ corporate headquarters and development functions are based in the UK, with research activities in Italy. More information can be found at: www.creabilis-sa.com
